Navigation Links
VivaGel(R) Demonstrates Anti-HIV and Herpes Activity Following Human Administration
Date:8/4/2009

MELBOURNE, Australia, Aug. 4 /PRNewswire-FirstCall/ -- Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY) today announced the results of its clinical trial demonstrating that VivaGel(R) retains antiviral activity against human immunodeficiency virus (HIV) and herpes simplex virus (HSV, the virus that causes genital herpes), following vaginal administration in women.

The clinical study was conducted to assess the antiviral activity of VivaGel(R) (SPL7013 Gel) in cervicovaginal fluid samples (CVS) taken from healthy women immediately, then at 1, 3, 12 and 24 hours after separate vaginal doses of the product. These samples were tested for their ability to prevent HIV and genital herpes (HSV-2) infection of susceptible cells in the laboratory.

The study showed that CVS obtained immediately after vaginal administration of VivaGel(R) provided effectively complete inhibition of HIV and HSV infection in vitro.

At 1 and 3 hours following administration of product, the initial high level of inhibition of HIV and HSV was retained in all women tested.

Even at 12 and 24 hours following administration, more than 90% of the initial antiviral activity was retained for both HIV and HSV in more than half of the women enrolled in the study.

This is the first clinical study to demonstrate potent antiviral activity of any microbicide beyond one hour after administration of the product in humans. These data indicate the potential for VivaGel(R) to be used other than immediately prior to sexual intercourse (i.e., as a coitally-dissociated microbicide). However, future testing in clinical efficacy studies is required to confirm this.

"These results are extremely encouraging," said Dr Jackie Fairley, CEO of Starpharma. "They show not only an excellent level of activity, but also a sustainability of effect that exceeded our expectations. The retention of potent activity several hours after administration can only enhance the commercial prospects of VivaGel(R)," Dr Fairley added.

There were no serious adverse events during the study, and as previously announced the data indicate VivaGel(R) was well-tolerated.

The study was conducted in Melbourne at the Centre for Clinical Studies and in collaboration with the Burnet Institute. The study was funded by the U.S. National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Division of AIDS (DAIDS), under Contract No. HHSN266200500042C.*

* The following statement is included in accordance with the requirements of Contract No. HHSN266200500042C:

The content of this announcement does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government.

    For further information:

    Media
    Buchan Consulting
    Rebecca Wilson
    Tel: +61 3 9866 4722
    Mob: +61 417 382 391
    rwilson@bcg.com.au

    Ellie Papathanasiou
    Tel: +61 2 9237 2800
    epapathanasiou@bcg.com.au

    Starpharma
    www.starpharma.com

    Dr Jackie Fairley
    Chief Executive Officer
    +61 3 8532 2704

    Ben Rogers
    Company Secretary
    +61 3 8532 2702
    ben.rogers@starpharma.com


'/>"/>
SOURCE Starpharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Warning for N-9 - an Opportunity for VivaGel(R)
2. Starpharma and Durex Sign Co-Development Agreement for VivaGel(R)-Coated Condoms
3. CAeHC Demonstrates NHIN-enabled Gateways Among Five California Health Information Exchanges
4. Study demonstrates the anti-inflammatory properties of pine bark extract
5. Study Demonstrates the Anti-Inflammatory Properties of Pine Bark Extract on Inflammatory Mediators COX-2 and 5-LOX
6. Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
7. Clinical Study Demonstrates Superior Bioavailability of Jarrow's Proprietary QH-absorb Formula
8. DaVita Study Demonstrates Clinical Application of Sysmex Reticulocyte Hemoglobin Equivalent (RET-He) Parameter
9. Penn study demonstrates new way to boost immune memory
10. Study Demonstrates Internet Risks for Teen Girls
11. Abbotts XIENCE V(R) Demonstrates Impressive Low Rates of Repeat Procedure, Stent Thrombosis and Major Adverse Cardiac Events in Complex, Real World Patients in SPIRIT V Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... , ... CHARM CITY RUN WELCOMES MERCY MEDICAL CENTER AS , BALTIMORE WOMEN’S ... serve as the official title sponsor of the Baltimore Women’s Classic, the largest all ... women will walk or run the course around the Baltimore Inner Harbor. Mercy has ...
(Date:3/29/2017)... ... March 29, 2017 , ... Wells Pharmacy Network, a ... at the upcoming World Congress, in Hollywood Florida April 6-8, 2017. , Ben ... the visionary leader in the training of physicians, scientists, and members of the ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... FASTBRACES® in Carnegie, OK, from Dr. Jamie Cameron, with or without a ... compared to traditional orthodontic treatment. Depending on each patient’s case, treatment with the ...
(Date:3/29/2017)... ... March 29, 2017 , ... Altima Technologies, Inc., the ... and data center assets and audio-video devices has recently updated its Visio Stencils ... for free and download shapes and stencils from http://www.VisioStencils.com. , New ...
(Date:3/29/2017)... Yorba Linda, Ca (PRWEB) , ... March 29, ... ... a standard process in many scientific laboratories. The assembly protocols involve many repetitive ... is well suited for automation, which enables the high-throughput needed, and results in ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 Research and ... Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast" ... ... 2021 from its current market size in 2016. The Untapped Proton Therapy ... than 1 Billion USD in 2016. Proton Therapy plays ...
(Date:3/29/2017)... 2017  Zynex (OTCQB: ZYXI), an innovative medical technology company ... devices for pain management, stroke rehabilitation, cardiac monitoring and ... Company,s 2016 full-year investor webcast on Monday, April 3, 2017 at 9:00 ... Company expects to file its 2016 full year financial ... ...
(Date:3/29/2017)... March 29, 2017 According to a new market ... (Gas-Filled Detectors, Geiger Muller, Survey Meter, Solid-State), Products (Personal Dosimeters, OSL, Badges), ... published by MarketsandMarkets, the market is expected to reach USD 1,215.4 Million ... 6.5% from 2016 to 2021. Continue Reading ... ...
Breaking Medicine Technology: